Research Honors Head and Neck Cancer Funding
Research and treatment of head and neck cancers at the University of Colorado Cancer Center reached a new level this month with a highly competitive Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI). The SPORE was approved by NCI Scientific Program leadership for FY2021 funding; the projected starting date is July 1
Greg Glasgow | 
June 07, 2021
Not all cancerous tumors are created equal. Some tumors, known as “hot” tumors, show signs of inflammation, which means they are infiltrated with T cells working to fight the cancer. Those tumors are easier to treat, as immunotherapy drugs can then amp up the immune response.
Greg Glasgow | April 22, 2021
Two University of Colorado Cancer Center researchers have received a five-year R01 Award for $497,893 per year from the National Institutes of Health (NIH) to study a potential new drug treatment for salivary gland cancer. The award is part of an inter-campus collaboration between Antonio Jimeno, MD, PhD, co-leader of the Developmental Therapeutics Program, and Tin Tin Su, PhD, co-leader of the Molecular and Cellular Oncology Program.
Valerie Gleaton | April 16, 2021
Studies have long reported that Black cancer patients have poorer outcomes than their white counterparts. But two University of Colorado Cancer Center researchers decided to investigate the data further and figure out why. What they found was that the outcome disparity was caused not by biology, but simply by differences in access to health care.
Cancer Center | October 01, 2020
Research Head and Neck Cancer Cancer
Nearly two thousand people living in Colorado will be diagnosed with head and neck cancer (HNC) in 2020. Generally, a very aggressive disease, head and neck cancer require expert care that is not widely available in community cancer clinics. However, patients that are not well-represented in clinical studies, especially Hispanic patients, are less likely to get care from centers that specialize in the disease, such as the University of Colorado Cancer Center.
Cancer Center | June 29, 2020
CBS4 Denver
May 21, 2021
The U.S. Preventive Services Task Force recently lowered its recommended age to begin screening for colon cancer from 50 to 45. It’s the third most common cancer in America, and in Colorado, there are an estimated 2,100 new cases each year.
Dr. Chris Lieu, the Associate Director of Clinical Research at the CU Cancer Center, explained the change stems from an increase in the number of colorectal cancer cases among younger people.
CBS4 Denver
January 08, 2021
Peyton taught the world that ovarian cancer doesn’t just strike mothers and grandmothers. “She’s brought so much awareness to the disease through her advocacy,” said CU Cancer Center member Saketh Guntupalli, MD.
Cure Today
December 24, 2020
It is one of the most common types of leukemias in adults; however, the disease comprises only about 1% of all cancers. There are a variety of treatment options available for patients with AML, with more clinical trials evaluating new therapies in the pipeline. In this episode of the “CURE talks Cancer” podcast, we spoke with Dan Pollyea, from the University of Colorado Cancer Center, about these treatment options.
Fox 31 | Channel 2
October 06, 2020
Mia and her parents shared their experience with RadFlix with FOX31. They explained that watching TV or a movie while getting radiation treatment was a game-changer. RadFlix was developed by Douglas Holt, MD, Brian Miller, PhD, and Sarah Milgrom, MD.
